Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes
Open Access
- 1 February 2022
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 20 (1) , 94-94.e10
Abstract
No abstract availableKeywords
Funding Information
- Ipsen
This publication has 22 references indexed in Scilit:
- Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramClinical Genitourinary Cancer, 2018
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateEuropean Journal of Cancer, 2018
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN TrialJournal of Clinical Oncology, 2017
- Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing mapsOncotarget, 2016
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialThe Lancet Oncology, 2016
- Cabozantinib versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Impact of Charlson’s comorbidity index on overall survival following tumor nephrectomy for renal cell carcinomaInternational Urology and Nephrology, 2009
- Kidney cancer: Identification of novel targets for therapyKidney International, 2006
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987